(IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue. Designed to protect against primary and recurrent infections caused by Chlamydia … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asymptomatic infection, chlamydia, Chlamydia trachomatis, Fast Track Designation, Griffith University, immunogenicity, infertility, Jean-François Toussaint, mRNA vaccine candidate, pelvic inflammatory disease, phase 1/2 clinical study, pregnancy complications, public health need, Queensland Government, safety, Sanofi, Translational Science Hub, University of Queensland, US Food and Drug Administration
(IN BRIEF) Evonik has partnered with the University of Mainz to commercialize a new class of polyethylene glycols (PEGs) called randomized polyethylene glycols (rPEGs). These rPEGs will be integrated into Evonik’s specialized lipid platform for drug delivery in nucleic acid-based … Read the full press release
Posted in Chemicals, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Evonik, immunogenicity, lipid, lipid nanoparticle carriers, lipids, LNP carriers, nucleic acid delivery, nucleic acid-based medicines, PEGs, Polyethylene glycols, polymers, Prof. Dr. Holger Frey, randomized polyethylene glycols, rPEG lipids, rPEG-lipids, rPEGs, specialty chemicals, Thomas Riermeier, University of Mainz
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?